Clinical trial

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

NCT02568839

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2014-11-01

PhasePHASE2 / PHASE3

Study timeline

Study start (unknown)2014-11-01Date precision: month

Registry last updated2020-08-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Early-Stage Breast Carcinomaunresolved

HER-2 Positive Breast Cancerunresolved

Interventions

docetaxel + trastuzumab sc + pertuzumabDRUG

trastuzumab emtansinDRUG

Sponsors & collaborators

Thomas Hatscheklead sponsor

Mapped research locations

StockholmSweden1 GothenburgSweden1 LundSweden1 UppsalaSweden1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02568839 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.